Patents Assigned to Innogenetics S.A.
-
Publication number: 20120270208Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.Type: ApplicationFiled: May 23, 2012Publication date: October 25, 2012Applicant: INNOGENETICS, S.A.Inventors: Robert J. DELEYS, Dirk Pollet, Geert Maertens, Hugo Van Heuverswjn
-
Patent number: 8163873Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: GrantFiled: November 10, 2008Date of Patent: April 24, 2012Assignee: N.V. Innogenetics S.A.Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
-
Publication number: 20110143443Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: ApplicationFiled: November 10, 2008Publication date: June 16, 2011Applicant: N.V. Innogenetics S. A.Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
-
Patent number: 7855052Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.Type: GrantFiled: November 30, 2006Date of Patent: December 21, 2010Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Publication number: 20090137051Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: ApplicationFiled: November 10, 2008Publication date: May 28, 2009Applicant: N.V. Innogenetics S. A.Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
-
Publication number: 20070243524Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.Type: ApplicationFiled: November 30, 2006Publication date: October 18, 2007Applicant: N.V. INNOGENETICS S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7279170Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.Type: GrantFiled: June 22, 2006Date of Patent: October 9, 2007Assignee: N.V. Innogenetics S.A.Inventors: Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
-
Patent number: 7258982Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: April 13, 2004Date of Patent: August 21, 2007Assignee: Innogenetics, S.A.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 7255997Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as show in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: August 15, 2000Date of Patent: August 14, 2007Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7195765Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: July 6, 2001Date of Patent: March 27, 2007Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7157226Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: April 27, 1994Date of Patent: January 2, 2007Assignee: Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7122306Abstract: The present application provides polynucleic acid sequences of 8 or more contiguous nucleotides selected from an HCV subtype 3c genomic sequence selected from the region spanning positions 1 to 957 of the Core of Core/E1 region of HCV subtype 3c, wherein said polynucleic acid sequence is capable of hybridizing to HCV type 3c, but not another type or subtype of HCV; or the complement of the polynucleic acid, wherein the polynucleic acid contains at least one genotype-specific nucleotide. Methods and means of using and making the described sequences are also provided.Type: GrantFiled: June 5, 2001Date of Patent: October 17, 2006Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7083797Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.Type: GrantFiled: December 23, 2002Date of Patent: August 1, 2006Assignee: N.V. Innogenetics S.A.Inventors: Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
-
Publication number: 20060078932Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.Type: ApplicationFiled: October 13, 2005Publication date: April 13, 2006Applicant: N.V. INNOGENETICS S.A.Inventors: Geert Maertens, Erik Depla
-
Publication number: 20060008853Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itslf isolated from the cerebral cortex of a patient having Alzheimer's disease. Further, a method of detecting the tau protein is claimed.Type: ApplicationFiled: August 20, 2004Publication date: January 12, 2006Applicant: N.V. Innogenetics S.A.Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde
-
Patent number: 6900293Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: GrantFiled: December 11, 2000Date of Patent: May 31, 2005Assignee: N.V. Innogenetics S.A.Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, André Van De Voorde
-
Patent number: 6855318Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.Type: GrantFiled: May 5, 2000Date of Patent: February 15, 2005Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Erik Depla
-
Publication number: 20050003345Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.Type: ApplicationFiled: April 13, 2004Publication date: January 6, 2005Applicant: INNOGENETICS, S.A.Inventors: Robert Deleys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn
-
Publication number: 20040191768Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:Type: ApplicationFiled: April 13, 2004Publication date: September 30, 2004Applicant: INNOGENETICS, S.A.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6762024Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: June 12, 2001Date of Patent: July 13, 2004Assignee: Innogenetics, S.A.Inventors: Geert Maertens, Lieven Stuyver